AC Immune (NASDAQ:ACIU) CEO Andrea Pfeifer Sells 10,000 Shares
by Doug Wharley · The Cerbat GemAC Immune (NASDAQ:ACIU – Get Free Report) CEO Andrea Pfeifer sold 10,000 shares of AC Immune stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $2.79, for a total transaction of $27,900.00. Following the completion of the sale, the chief executive officer directly owned 3,820,288 shares in the company, valued at approximately $10,658,603.52. This represents a 0.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
AC Immune Stock Performance
ACIU stock traded down $0.02 during mid-day trading on Monday, hitting $2.77. The company had a trading volume of 224,826 shares, compared to its average volume of 313,492. The firm has a market cap of $281.90 million, a PE ratio of -3.38 and a beta of 1.65. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.02 and a current ratio of 0.87. AC Immune has a 12 month low of $1.60 and a 12 month high of $4.00. The stock’s fifty day moving average price is $2.95 and its two-hundred day moving average price is $3.08.
AC Immune (NASDAQ:ACIU – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.01. The business had revenue of $1.40 million for the quarter, compared to analyst estimates of $0.33 million. AC Immune had a negative net margin of 1,788.02% and a negative return on equity of 125.26%. On average, analysts forecast that AC Immune will post -0.68 earnings per share for the current fiscal year.
Institutional Investors Weigh In On AC Immune
A number of institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. boosted its stake in shares of AC Immune by 46.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after purchasing an additional 5,920 shares in the last quarter. EFG International AG purchased a new stake in shares of AC Immune in the 4th quarter valued at $41,000. Private Advisor Group LLC purchased a new stake in shares of AC Immune in the 3rd quarter valued at $48,000. Susquehanna International Group LLP purchased a new stake in shares of AC Immune in the 3rd quarter valued at $63,000. Finally, Sei Investments Co. purchased a new stake in shares of AC Immune in the 2nd quarter valued at $51,000. Hedge funds and other institutional investors own 51.36% of the company’s stock.
Analyst Ratings Changes
A number of research firms recently weighed in on ACIU. Jefferies Financial Group reaffirmed a “buy” rating and set a $7.00 target price on shares of AC Immune in a report on Friday, March 13th. Weiss Ratings lowered shares of AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 8th. BTIG Research reissued a “buy” rating and issued a $8.00 price target on shares of AC Immune in a report on Monday, May 4th. Finally, Wall Street Zen raised shares of AC Immune from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $7.50.
View Our Latest Stock Report on ACIU
About AC Immune
AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.
Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.